Efficacy and safety of rademikibart (CBP-201), a next-generation mAb targeting IL-4Rα, in adults with moderate to severe atopic dermatitis: A phase 2 randomized trial (CBP-201-WW001)
Jonathan I. Silverberg, Bruce Strober, Brian A. Feinstein, Jinhua Xu, Emma Guttman‐Yassky, Eric L. Simpson, P. Li, Malinda Longphre, Jing Song, Jiawang Guo, Jang Yun, Belinda Williams, Wubin Pan, Selwyn Ho, Raúl Collazo, Zheng Wei
Topics & Concepts
Atopic dermatitisMedicineRandomized controlled trialImmunologyInternal medicineDermatology and Skin DiseasesPsoriasis: Treatment and PathogenesisAsthma and respiratory diseases